Parkinson disease (PD) is a chronic and often progressive neurodegenerative disorder that, in more advanced stages, is often associated with postural instability and gait dysfunction. These problems impart an increased risk for falls \[[@b1-ad-11-3-679]\]. The major risk factor for PD is increasing age, and worldwide prevalence estimates range from 0.43% for individuals aged 60 to 69 years, 1% for those 70 to 79 years, and 1.9% for those \>80 years \[[@b2-ad-11-3-679]\]. In an aging population with increased survival, the prevalence of PD is expected to increase \[[@b3-ad-11-3-679]\].

The PD population experiences nearly double the risk for falls and associated bone fractures compared with the general population of similar age and health \[[@b4-ad-11-3-679]\]. Consequently, the risk of falls in PD patients represents a major health burden, with a reported annual incidence of 43% to 68% of patients experiencing ≥1 fall \[[@b5-ad-11-3-679]-[@b11-ad-11-3-679]\]. Among patients with PD who have already experienced a fall, this problem is recurrent in approximately 30% to 40% of patients \[[@b8-ad-11-3-679],[@b12-ad-11-3-679]\].

One clinical problem associated with falls is orthostatic hypotension (OH), defined as a sustained reduction in blood pressure (BP) within 3 minutes after standing. It can cause symptoms such as dizziness, lightheadedness, and syncope \[[@b13-ad-11-3-679]\]. The link between OH and falls has been established in older persons by several studies \[[@b14-ad-11-3-679],[@b15-ad-11-3-679]\]. In addition, OH has been reported to occur in up to 47% to 58% of PD patients \[[@b16-ad-11-3-679]-[@b18-ad-11-3-679]\]. Neurogenic OH (nOH) is a subcategory of OH in which the orthostatic BP reduction results from autonomic failure due to a peripheral or central (or combined) neurological disorder, such as PD, multiple system atrophy, or peripheral autonomic neuropathy \[[@b19-ad-11-3-679]\].

This review discusses the burden of and key risk factors for falls among patients with PD, with a focus on the recognition, assessment, and management of OH/nOH as an important contributing factor.

Assessment of Orthostatic Hypotension in Parkinson Disease
==========================================================

Because OH can be an important contributor to falls for patients with PD, it is important to recognize the causes and incorporate screening and assessment of postural hypotensive signs and symptoms into the clinical management of PD patients. A recent meta-analysis of 25 studies reported an estimated prevalence of OH in PD patients of 30% \[[@b20-ad-11-3-679]\], emphasizing the need for routine screening.

###### 

Causes of OH and nOH \[[@b24-ad-11-3-679]-[@b26-ad-11-3-679]\].

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cause                 OH                                                   nOH
  --------------------- ---------------------------------------------------- ---------------------------------------------------------------------------------------------
  Medications           •Dopaminergic agents\                                •nOH may be exacerbated by medications that cause OH
                        •Antidepressants (tricyclic antidepressants)\        
                        •Anticholinergics\                                   
                        •Antihypertensives\                                  
                        •Diuretics\                                          
                        •Nitrates\                                           
                        •Phosphodiesterase inhibitors\                       
                        •Vasodilators\                                       
                        •Negative inotropic/chronotropic agents\             
                        •Central sympatholytics\                             
                        •Renin-angiotensin system antagonists                

  Clinical etiologies   •Hypovolemia\                                        •Primary neurogenic causes\
                         ◦Dehydration\                                        ◦Sympathetic noradrenergic denervation\
                         ◦Bleeding\                                            ■Parkinson disease\
                        •Impaired cardiac output/cardiac pump failure\         ■Pure autonomic failure\
                         ◦Cardiac arrhythmia\                                 ◦Intact sympathetic noradrenergic innervation\
                         ◦Aortic stenosis\                                     ■Multiple system atrophy\
                         ◦Heart failure\                                       ■Dopamine beta-hydroxylase deficiency (intact innervation but norepinephrine deficiency)\
                        •Venous pooling\                                     •Secondary neurogenic causes\
                         ◦Prolonged recumbency or standing\                   ◦Peripheral neuropathies\
                         ◦Postprandial dilation of splanchnic vessel beds\    ◦Spinal cord problems
                         ◦Heat exposure\                                     
                         ◦Fever                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

nOH=neurogenic orthostatic hypotension; OH=orthostatic hypotension.

Definition of Orthostatic Hypotension
-------------------------------------

The American Academy of Neurology and American Autonomic Society consensus statement defines OH as a reduction of systolic BP of ≥20 mmHg or diastolic BP of ≥10 mmHg that occurs within 3 minutes of standing or head-up tilt (HUT) \[[@b19-ad-11-3-679],[@b21-ad-11-3-679]\]. Although this definition focuses on the magnitude of the decline in BP, the actual mean BP while standing may be more clinically relevant to symptomatology; in particular, an actual mean BP \<75 mmHg while standing offered high sensitivity and specificity for identifying symptomatic patients \[[@b22-ad-11-3-679]\]. Interestingly, both symptomatic and asymptomatic OH patients reported similar extent of functional impairment in activities of daily living (ADL)/instrumental ADL (iADL) and the Ambulatory Capacity Measure assessments \[[@b23-ad-11-3-679]\]. The implications of the latter observations are that it is important not to limit an analysis to only symptomatic OH patients when evaluating the contribution of OH to disability in patients with PD \[[@b23-ad-11-3-679]\].

Causes of Orthostatic Hypotension/Neurogenic Orthostatic Hypotension
--------------------------------------------------------------------

The origin of OH may be non-neurogenic or neurogenic, and individual patients may have both non-neurogenic and neurogenic causes of OH. It is important to identify the major cause or causes, as this may affect management; common causes are listed in [Table 1](#T1-ad-11-3-679){ref-type="table"} \[[@b13-ad-11-3-679],[@b24-ad-11-3-679]-[@b26-ad-11-3-679]\]. Among the most common causes of nOH is chronic autonomic failure intrinsic to PD \[[@b25-ad-11-3-679],[@b27-ad-11-3-679]\]. Non-neurogenic causes of OH include the influence of certain medications or clinical conditions that impair cardiac output. Medications used to treat hypertension, depression, or bladder symptoms can induce or exacerbate OH \[[@b26-ad-11-3-679]\]. Anti-hypertensives, in particular, are a common cause of OH \[[@b26-ad-11-3-679]\]. Reduced blood volume associated with inadequate daily fluid intake is also a common factor \[[@b24-ad-11-3-679],[@b28-ad-11-3-679]\]. In addition, levodopa and other dopaminergic therapy for PD can cause hypotensive responses \[[@b29-ad-11-3-679]\]. Based on our clinical experiences, even conventional doses of levodopa pose a risk, especially if an inadequate dose of a peripheral dopamine decarboxylase inhibitor is co-administered (eg, \<75 mg/day carbidopa). Drugs that augment levodopa effects (such as monoamine oxidase B and catecholamine-O-methyltransferase inhibitors) or dopaminergic agonists (pramipexole, ropinirole, and rotigotine) also can produce OH \[[@b30-ad-11-3-679],[@b31-ad-11-3-679]\]. Thus, both the presence of PD and its most common treatments can add to the risk for OH.

Symptoms of Orthostatic Hypotension
-----------------------------------

The range of symptoms associated with OH is listed in [Table 2](#T2-ad-11-3-679){ref-type="table"} \[[@b13-ad-11-3-679],[@b24-ad-11-3-679],[@b26-ad-11-3-679],[@b27-ad-11-3-679],[@b32-ad-11-3-679],[@b33-ad-11-3-679]\]. The most common experiences are dizziness/lightheadedness, presyncope, and syncope, although patients may present with less specific symptoms, such as weakness or fatigue \[[@b13-ad-11-3-679]\]. Symptoms in elderly patients with OH may be more likely to result from age-related factors, such as decreased baroreflex sensitivity, impaired vascular function, and reduced blood flow, resulting in inadequate perfusion of the brain (eg, lightheadedness and syncope) \[[@b34-ad-11-3-679]\]. In an analysis of OH-related hospitalizations in the United States, physiologic changes occurring during aging and risk factors such as neurodegenerative disease were linked to the age-related increase in hospitalizations due to OH \[[@b35-ad-11-3-679]\]. This analysis also reported that PD patients ≥75 years old accounted for 5.2% of OH-related hospitalizations \[[@b35-ad-11-3-679]\].

###### 

Symptoms of OH and nOH \[[@b13-ad-11-3-679],[@b24-ad-11-3-679],[@b26-ad-11-3-679],[@b27-ad-11-3-679]\]\*.

  ------------- -----------------------------------------------------------------------------------------------------
  Common        •Postural lightheadedness or dizziness\
                •Syncope/presyncope\
                •Visual disturbance\
                •Sensation of blacking out\
                •Falls with or without syncope

  Less common   •Orthostatic cognitive dysfunction\
                •Mental dulling\
                •Generalized weakness\
                •Neck pain or discomfort in the suboccipital and paracervical region \["coat hanger" distribution)\
                •Fatigue\
                •Nausea\
                •Headache\
                •Dyspnea
  ------------- -----------------------------------------------------------------------------------------------------

nOH=neurogenic orthostatic hypotension; OH=orthostatic hypotension. \*Some patients may be asymptomatic \[[@b32-ad-11-3-679],[@b33-ad-11-3-679]\].

Screening and Diagnosis of Orthostatic Hypotension
--------------------------------------------------

Recent guidelines issued by the American Autonomic Society and the National Parkinson Foundation consensus panel recommend screening patients at increased risk of OH, especially those with suspected or diagnosed neurodegenerative disorder associated with autonomic dysfunction (eg, PD) \[[@b26-ad-11-3-679]\]. The screening process includes inquiries about key symptoms of OH, the frequency and severity of their occurrence, how long the patient is able to stand, and the impact of these symptoms on the patient's regular activities \[[@b26-ad-11-3-679]\]. Examples of suggested screening questions are included in [Table 3](#T3-ad-11-3-679){ref-type="table"} \[[@b26-ad-11-3-679]\]. These recommendations also suggest that specific questions be asked regarding the circumstances of falls, but clinicians are cautioned to consider that patients might not be forthcoming regarding their symptoms or falls for fear of losing their autonomy \[[@b26-ad-11-3-679]\]. Physicians should also consider a number of contributing factors that may cause patient falls, including postural instability, gait impairment, poor vision and proprioception, cognitive impairment, and physical environmental factors \[[@b36-ad-11-3-679]\].

Thorough descriptions of diagnostic strategies to investigate OH have been published \[[@b26-ad-11-3-679],[@b37-ad-11-3-679]\]. An accepted standard for reliable assessment is for a patient to remain in the supine position for ≥5 minutes and then to stand for 3 minutes, with measurement of BP just before standing and at both 1 and 3 minutes of standing. When a supine BP measurement is not feasible, seated-to-standing BP measurements can be a suitable alternative \[[@b26-ad-11-3-679]\]. In a recent study, measuring BP within 1 minute of standing was effective (and, in some ways, a more clinically relevant assessment) \[[@b38-ad-11-3-679]\]. Clinicians can evaluate both the change in BP from supine/seated-to-standing and the actual mean BP at 1 minute of standing as a method of screening for OH \[[@b22-ad-11-3-679],[@b26-ad-11-3-679]\]. A decline of ≥20 mmHg systolic BP or 10 mmHg diastolic BP upon standing is diagnostic for OH, even if asymptomatic; a mean standing BP of ≤75 mmHg could also indicate OH \[[@b22-ad-11-3-679],[@b33-ad-11-3-679]\]. An important correlate of BP measurement is determination of heart rate, which can aid in identifying nOH \[[@b33-ad-11-3-679]\]. An inadequate compensatory increase in heart rate is typical of nOH, whereas an increase \>15 bpm is characteristic of transient conditions causing OH (such as dehydration). A recent study assessing orthostatic heart rate changes in individuals with autonomic failure resulting from neurodegenerative synucleinopathies (ie, PD, multiple system atrophy, dementia with Lewy bodies, and pure autonomic failure) reported that patients with nOH experienced twice the drop in systolic BP along with only one-third of the increase in heart rate compared with patients with non-neurogenic OH (both *P*\<0.0001) \[[@b39-ad-11-3-679]\]. These results suggest that a ratio of change in heart rate to change in systolic pressure that is \<0.5 bpm/mmHg is diagnostic of nOH and could be used to differentiate it from non-neurogenic OH \[[@b39-ad-11-3-679]\]. However, the utility of a heart rate measurement may be diminished in some elderly patients because of the potential for age-related impairment in baroreflex function \[[@b33-ad-11-3-679]\].

The cause of OH can be multifactorial. Even if changes in BP and a lack of compensatory change in heart rate suggest nOH, clinicians should nonetheless consider a concurrent non-neurogenic cause of OH by reviewing medications and other evidence from cardiac and neurological examinations, performing an electro-cardiogram (if appropriate), and conducting biochemical and hematological laboratory testing \[[@b26-ad-11-3-679],[@b40-ad-11-3-679]\]. Specialty testing may be needed to evaluate autonomic reflex arcs and to target a specific diagnosis of underlying autonomic failure. A thorough assessment may include one or more types of autonomic testing, with measurement of plasma catecholamines performed in supine and upright positions in conjunction with cardiovascular autonomic testing, sudomotor function testing (such as the Quantitative Sudomotor Axon Reflex Test or thermoregulatory sweat testing), or ambulatory BP monitoring for detecting episodic OH \[[@b26-ad-11-3-679],[@b33-ad-11-3-679],[@b41-ad-11-3-679]\]. Regarding the assessment of catecholamine levels, it should be noted that these measurements should always be interpreted in the context of other test results because patients with some conditions (eg, multiple system atrophy) may exhibit normal catecholamine plasma levels and severe nOH simultaneously \[[@b42-ad-11-3-679]\].

###### 

Screening Questions for Suspected OH/nOH \[[@b26-ad-11-3-679]\].

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Screening Questions[\*](#nt3-ad-11-3-679){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  1.Have you fainted/blacked out recently?\
  2.Do you feel dizzy or lightheaded upon standing?\
  3.Do you have vision disturbances when standing?\
  4.Do you have difficulty breathing when standing?\
  5.Do you have leg buckling or leg weakness when standing?\
  6.Do you ever experience neck pain or aching when standing?\
  7.Do the above symptoms improve or disappear when you sit or lay down?\
  8.Are the above symptoms worse in the morning or after meals?\
  9.Have you experienced a fall recently?\
  10.Are there any other symptoms that you commonly experience when you stand up or within 3-5 minutes of standing up that get better when you sit or lay down?

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

Any positive response should prompt further investigation with orthostatic blood pressure measurements. This table has been reproduced from Gibbons, et al. *J Neurol*. 2017; 264:1569 under the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Burden of parkinson disease-related falls
=========================================

Clinical
--------

Falls are associated with increased morbidity in PD patients \[[@b8-ad-11-3-679],[@b36-ad-11-3-679]\]. In a study of PD patients who had fallen in the previous year, approximately one-third of falls resulted in physical injury. Most of these (81%) were soft-tissue injuries \[[@b7-ad-11-3-679]\]. An analysis of 24,831 people aged ≥65 years who were identified through the longitudinal National Long-Term Care Survey found that, among PD patients (n=791), 36% experienced fractures over a period of 5 years \[[@b43-ad-11-3-679]\]. In this survey, hip fractures were reported by 16% of patients in the PD cohort (more than double the odds of a hip fracture in patients without PD) \[[@b43-ad-11-3-679]\]. The increased fracture risk in PD patients was more pronounced for lower-extremity fractures, suggesting that patients with this disorder may be unable to generate a timely reaction to buffer their fall by using their upper extremities. This, in turn, may be associated with a higher rate of injuries to the face, head, neck, trunk, and lower extremities \[[@b43-ad-11-3-679]\]. In addition, PD patients were reported to have more complications after fall-related injuries, including hospitalization \[[@b44-ad-11-3-679]\], which is then associated with higher rates of infection and mortality \[[@b45-ad-11-3-679]\].

Economic Impact
---------------

Both PD and falls in elderly individuals are associated with a significant economic burden. In 2006, the annual healthcare costs for PD patients aged \>65 years exceeded costs compared with their counterparts without PD (\$21,899 vs \$10,732) \[[@b46-ad-11-3-679]\]. Regardless of diagnosis, the average charge for a fall resulting in hospitalization for US patients aged 65 to 74 years was estimated to be more than \$24,000 (2008 prices) \[[@b47-ad-11-3-679]\]. In 2010, the PD population incurred \$8.1 billion more in medical costs than would be expected for a population without PD, 57% of which can be attributed to increased use of nursing home services \[[@b3-ad-11-3-679]\]. Moreover, recurrent falls can lead to nursing home admission, thereby further increasing costs \[[@b36-ad-11-3-679]\]. Based on recent Medicare estimates, the healthcare expenditure associated with nonfatal falls among adults aged ≥65 years is greater than \$30 billion \[[@b48-ad-11-3-679]\].

Given the increased prevalence of fall-related injury among elderly patients with PD, the cost burden associated with falls in this population is likely to be high, although cost data specific to PD-related falls are limited \[[@b44-ad-11-3-679],[@b49-ad-11-3-679]\], and cost data for populations with both PD and OH are even scarcer. In a French study from 1999, mean direct costs per year were significantly higher in patients with parkinsonism and OH compared with patients with parkinsonism but without OH (€737.67/month (€8852/year) vs €512.33/month (€6148/year), *P*\<0.05) \[[@b50-ad-11-3-679]\]. Additionally, the cohort with both parkinsonism and OH had substantially greater costs for ancillary care (+87% of mean difference in the OH cohort vs the cohort with PD alone), physician fees (+53%), and private hospitalization (+39%) \[[@b50-ad-11-3-679]\]. A recent US study compared medical costs of PD patients and nOH versus PD without nOH and found that patients with both PD and nOH have significantly higher medical costs for falls (\$2260 vs \$1049; *P*=0.0002) and total all-cause costs (\$31,260 vs \$20,910; *P*\<0.0001) due to more frequent falls, emergency department visits, and inpatient hospitalizations \[[@b51-ad-11-3-679]\]. Similarly, a retrospective study determined that hospitalization costs were approximately 3 times (+285%; *P*=0.04) higher and overall costs (per patient per year) approximately 2.5 times (+256%; *P*=0.04) higher in patients with PD and OH versus those with PD without OH \[[@b52-ad-11-3-679]\].

Figure 1.**Impact of falls and fall risk in patients with PD and nOH**. nOH=neurogenic orthostatic hypotension; PD=Parkinson disease \[[@b36-ad-11-3-679],[@b55-ad-11-3-679]-[@b57-ad-11-3-679]\].

Quality of Life Impact
----------------------

Patient quality of life (QoL) may be affected not only by falls themselves but also by fear of falling. In PD patients, fear of falling has been described as a lack of confidence in the ability to engage in daily activities without falling \[[@b53-ad-11-3-679]\] and is greater in patients who have experienced a fall (even as a rare event) compared with those who have not had this experience \[[@b54-ad-11-3-679]\]. Not surprisingly, fear of falling is a predictor of future falls \[[@b55-ad-11-3-679]\]. Both falls and fear of falling are strongly associated with limitations on activities of daily living and physical inactivity in patients with PD on a crude basis and after adjusting for physical impairments of other categories \[[@b54-ad-11-3-679]\]. Reduced activity due to fear of falling can compound the problems of declining physical health (deconditioning and further loss of activity), which in turn may be factors increasing the risk of falls ([Fig. 1](#F1-ad-11-3-679){ref-type="fig"}) \[[@b36-ad-11-3-679],[@b55-ad-11-3-679]-[@b57-ad-11-3-679]\].

The negative QoL effect of falls and associated fear of falling was brought out in a study of elderly patients (n=251) with PD (median duration, 8 years) showing that fear of falling led to avoidance of ordinary ADL, reduced physical activity, and social isolation \[[@b58-ad-11-3-679]\]. Among patients with PD, a history of falls or gait difficulties has been associated with poor or reduced QoL \[[@b59-ad-11-3-679],[@b60-ad-11-3-679]\]. Even when patients have relatively mild PD, a history of one or more previous falls is strongly associated with risk for subsequent falls and fall-related impaired QoL \[[@b61-ad-11-3-679]\]. In addition, OH symptoms have been shown to have a negative impact effect on QoL assessment and ADL of PD patients \[[@b62-ad-11-3-679]\]. Further, PD patients with OH had significantly greater levels of functional impairment compared with PD patients without OH as assessed using the ADL/iADL and the Ambulatory Capacity Measure \[[@b23-ad-11-3-679]\].

Risk Factors for Falls in Parkinson Disease
-------------------------------------------

In patients with PD, inherent clinical features of PD (especially gait disturbances and postural instability) contribute to the risk of falls. Additionally, patients with PD were shown to have a similar cognitive profile (ie, impaired executive function and attention) to that of elderly individuals (≥65 years old) with a history of unexplained falls, suggesting a role for cognitive impairment in the fall risk of patients with PD \[[@b63-ad-11-3-679]\]. Moreover, a meta-analysis of 6 prospective studies of falls in PD found that the strongest predictor of falls was ≥2 falls during the previous year \[[@b64-ad-11-3-679]\]. In addition, freezing of gait (FOG) has been identified as a strong and independent risk factor for falls \[[@b65-ad-11-3-679]\]. In a study of elderly patients who had ≥1 fall during a 12-month period, more than half (57%) of falls were attributed to intrinsic postural instability (ie, poor balance) or dizziness, followed by accidental causes (eg, stumbling; 39%), and then by syncope (3%) \[[@b7-ad-11-3-679]\]. Finally, cardiovascular autonomic neuropathy has also been shown to be a strong independent predictor of falls, being significantly (odds ratio (OR), 15.194; *P*=0.011) associated with a 15-fold higher probability of falls in patients with PD, whereas patients with PD and OH had a 10-fold higher probability of falls (OR, 10.702; *P*=0.02) \[[@b66-ad-11-3-679]\].

Several risk factors are associated with recurrent falls in PD patients, including longer duration of PD, greater clinical severity, overall functional limitations, more impairment of balance and gait, and levodopa-induced dyskinesia \[[@b7-ad-11-3-679],[@b8-ad-11-3-679],[@b65-ad-11-3-679]\]. An 8-year prospective study found that the percentage of patients reporting falls increased from 41% at baseline to 72% after 8 years \[[@b65-ad-11-3-679]\]. Certain factors associated with falls in patients with PD (such as FOG, gait disturbance, and impaired posture) are associated with increasing disease severity \[[@b67-ad-11-3-679]\]. Motor problems in PD patients, such as FOG, not only increase risk of falls but also are associated with increased risk of fall-related injury \[[@b67-ad-11-3-679]\].

Orthostatic hypotension is an independent risk factor for falls in older individuals \[[@b14-ad-11-3-679],[@b15-ad-11-3-679]\] and is prevalent among patients with PD, with prevalence estimates ranging from 9.6% to 58% \[[@b16-ad-11-3-679]-[@b18-ad-11-3-679],[@b20-ad-11-3-679]\]. Patients with PD and OH (whether of neurogenic origin or not) may be more likely to experience a fall than those with PD alone \[[@b51-ad-11-3-679],[@b68-ad-11-3-679]\]. A systematic review and meta-analysis evaluated studies that assessed the association between falls and OH published between 1946 and early 2017 \[[@b69-ad-11-3-679]\]. A subgroup analysis showed that PD patients had the highest odds ratio for the association between falls and OH (OR, 2.30 (95% CI, 1.53-3.48\]) compared with the other study populations (ie, community-dwelling adults, geriatric outpatients, geriatric inpatients, nursing home residents, patients with other diseases) \[[@b69-ad-11-3-679]\]. A 2017 study found that 25% of PD + nOH patients experienced a medically attended fall in the past 12 months, whereas 20% of patients with PD alone experienced a fall in the same time frame (*P*=0.016) \[[@b51-ad-11-3-679]\]. In addition, dopaminergic antiparkinsonian medications can contribute to OH or worsen nOH and can be associated with involuntary movements (dyskinesias), both of which have also been linked to increased risk of falls \[[@b67-ad-11-3-679]\]. However, not all studies have found a significant association of OH with increased fall risk in PD. PD patients have several risk factors for falls; therefore, the contribution of OH to fall risk is not easily ascertained from published study data \[[@b68-ad-11-3-679]\]. A prospective cohort study of patients with nOH found that 54% had experienced a fall in the past month \[[@b70-ad-11-3-679]\].

Assessment of the Risk of Falls: Importance of Different Patterns of Falls
==========================================================================

Various assessment tools can be useful to evaluate risk for falls. These include the modified Timed Up and Go test \[[@b71-ad-11-3-679]\], vestibular sensorial organization test, limits of stability of mobile posturography \[[@b72-ad-11-3-679]\], and free-field body sway analysis (such as the VertiGuard device (Vesticure GmbH, Pforzheim, Germany) \[[@b72-ad-11-3-679]\], and all have been useful at determining increased risk for falling in PD patients \[[@b71-ad-11-3-679],[@b72-ad-11-3-679]\]. In addition, a study in PD patients with a history of falls in the previous 6 months showed that the brief-balance evaluation system test reliably predicted risk for future falls \[[@b73-ad-11-3-679]\]. A prospective 12-month study showed that elderly PD patients who were at risk of falls scored higher on a FOG questionnaire compared with age-matched controls \[[@b74-ad-11-3-679]\]. Backward postural instability (retropulsive imbalance), in addition to FOG, is associated with falls in elderly PD patients and can be assessed using the Nutt Retropulsion Test \[[@b53-ad-11-3-679]\]. In a retropulsion test, the patient (standing upright) is pulled backward and the number of corrective steps is counted \[[@b75-ad-11-3-679]\]. Because anticipated retropulsion can yield different results than unanticipated retropulsion, the Nutt Retropulsion Test includes an unexpected shoulder pull \[[@b75-ad-11-3-679],[@b76-ad-11-3-679]\].

Fall patterns may provide insight regarding both etiology and appropriate intervention. For example, falls occurring immediately after rising from sitting or lying positions suggest a strong possibility of either OH or severe balance impairment or both \[[@b36-ad-11-3-679]\]. Patients who report tripping over doorsteps or stairs may benefit from general fall reduction approaches, such as the installation of handrails in the home, use of walking frames, or physical therapy targeted at fall avoidance, such as Lee Silverman Voice Training BIG (LSVT-BIG; [www.lsvtglobal.com](https://www.lsvtglobal.com)) \[[@b36-ad-11-3-679],[@b77-ad-11-3-679],[@b78-ad-11-3-679]\].

Interventions and Treatment for Orthostatic Hypotension and Fall Risk
=====================================================================

Goals of Treatment
------------------

The overall goal of treatment is not the normalization of BP but rather to decrease the symptoms of OH \[[@b79-ad-11-3-679]\]. Treatment goals for patients with OH include reducing the risk for falls and fall-associated injuries, prolonging safe standing time, and improving patients' physical capabilities in terms of mobility and independent functioning \[[@b26-ad-11-3-679],[@b80-ad-11-3-679]\]. Because the use of pressor therapies to treat OH can cause or exacerbate supine hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg), patients should be monitored to detect if potentially dangerous BP increases occur when in the supine position, and it should be determined whether bedtime antihypertensive therapy intervention is warranted. Such therapy must be balanced against the potential to exacerbate the symptoms of OH \[[@b81-ad-11-3-679],[@b82-ad-11-3-679]\]. Aggressive antihypertensive treatment with the goal of reducing systolic BP below 140 mmHg may not be warranted, particularly in older patients with a history of OH, labile BP, frailty, cognitive impairment, functional limitations, syncope, and falls \[[@b83-ad-11-3-679]\]. In our clinical experience, supine BP below 180/100 mmHg (measured in the patient's normal sleep position, ideally with the head of the bed elevated by 20-30°) should not be cause for concern and may not necessitate pharmacologic therapy.

Non-pharmacologic Strategies of Orthostatic Hypotension/Neurogenic Orthostatic Hypotension and Reduction of Fall Risk
---------------------------------------------------------------------------------------------------------------------

A careful evaluation of current medications may be the first and only intervention needed to control OH \[[@b26-ad-11-3-679]\]. The decision to reduce the dose of or discontinue a medication should be individualized, but particular attention should be paid to any anti-hypertensive medications. Older adults are commonly treated for hypertension, but a dose of an anti-hypertensive medication that was appropriate in an otherwise healthy patient may be too high for a PD patient with attendant autonomic dysfunction because of the increased risk of OH \[[@b26-ad-11-3-679]\]. Patients with PD may also be taking monoamine oxidase B inhibitors, which, in our clinical experience, can lower BP and are only mildly effective for PD symptoms. Clinical experience also suggests that dopamine agonists and amantadine can be considered for discontinuation and that dose reduction of levodopa can even be considered in some cases. A full list of medications whose discontinuation or dose reduction might be of benefit is provided in [Table 1](#T1-ad-11-3-679){ref-type="table"} \[[@b26-ad-11-3-679]\]. Shifting the timing of dosing for medications capable of lowering BP or slowing pulse rate may be adequate to address OH symptoms \[[@b26-ad-11-3-679],[@b84-ad-11-3-679]\]. In some patients with OH, avoidance of factors that may induce symptoms (eg, hot environment, carbohydrate-rich meals, and medications capable of lowering BP and not otherwise needed) offers a starting approach to management \[[@b26-ad-11-3-679],[@b37-ad-11-3-679]\].

Examples of non-pharmacologic interventions that can address OH symptoms, such as physical counter-maneuvers and strength training are summarized in [Table 4](#T4-ad-11-3-679){ref-type="table"} \[[@b24-ad-11-3-679],[@b26-ad-11-3-679],[@b37-ad-11-3-679],[@b77-ad-11-3-679],[@b78-ad-11-3-679],[@b85-ad-11-3-679]-[@b87-ad-11-3-679]\]. Non-pharmacologic inter-ventions that are generally not effective include home-based resistance training and lower body-only compression garments (eg, knee-length compression stockings) \[[@b87-ad-11-3-679],[@b88-ad-11-3-679]\]; in a study of non-pharmacologic interventions, water bolus ingestion, abdominal compression, and physical countermaneuvers were effective in preventing BP drops, while compression stocking did not affect BP drops \[[@b89-ad-11-3-679]\]. Although outcomes from the use of non-pharmacologic interventions for fall prevention in patients with PD and OH have not been extensively studied, some non-pharmacologic interventions are capable of reducing fall risk in PD \[[@b77-ad-11-3-679],[@b85-ad-11-3-679],[@b86-ad-11-3-679]\]. In a study of elderly patients with PD, use of a 4-wheeled walker or the U-Step rollator (Instep Mobility, Skokie, IL) was associated with fewer episodes of freezing, near-falls, and completed falls compared with use of other assistive devices (eg, cane, standard walking frame, or a walking frame with 2 wheels) or no assistive device at all \[[@b86-ad-11-3-679]\]. In another study, vestibular rehabilitation for 8 weeks significantly improved several measures of balance (eg, Berg Balance Scale, Activities-Specific Balance Confidence Scale scores) and gait (Dynamic Gait Index) of elderly patients with PD \[[@b85-ad-11-3-679]\]. In addition, individualized exercises to improve ADL, such as LSVT-BIG, have shown promise in PD patients \[[@b77-ad-11-3-679],[@b78-ad-11-3-679]\]; however, evaluations for PD patients who are also affected with OH have not been performed.

###### 

Non-pharmacologic Interventions That May Reduce OH/nOH Symptoms or General Fall Risk in PD.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Interventions                                                                                                               Address OH/nOH Symptoms                                             Address General Fall Reduction in PD
  --------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------
  Physical counter-maneuvers \[[@b37-ad-11-3-679],[@b87-ad-11-3-679],[@b89-ad-11-3-679]\]                                     •Leg crossing with active muscle tensing\                           
                                                                                                                              •Bending forward, arms crossed over the abdomen\                    
                                                                                                                              •Squatting\                                                         
                                                                                                                              •Lower-body muscle tensing after squatting                          

  Compression garments \[[@b26-ad-11-3-679],[@b87-ad-11-3-679],[@b89-ad-11-3-679]\]                                           •Abdominal or full-body compression garments                        

  Other \[[@b24-ad-11-3-679],[@b26-ad-11-3-679],[@b89-ad-11-3-679]\]                                                          •Sleeping with elevation of the head end of the bed (6-9 inches)\   
                                                                                                                              •Liberal intake of salt, up to 10 g of sodium/day\                  
                                                                                                                              •Adequate hydration (target 2-3 L/day)\                             
                                                                                                                              •Oral water bolus (500 mL)                                          

  Assistive devices/safety measures for general fall reduction \[[@b37-ad-11-3-679],[@b86-ad-11-3-679]\]                                                                                          •Walking frames\
                                                                                                                                                                                                  •Canes that can be folded into a tripod chair\
                                                                                                                                                                                                  •Handrails

  Physical therapy or symptoms of PD that may affect fall risk \[[@b77-ad-11-3-679],[@b78-ad-11-3-679],[@b85-ad-11-3-679]\]                                                                       •Vestibular training, Lee Silverman Voice Training BIG (LSVT-BIG)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

nOH=neurogenic orthostatic hypotension; OH=orthostatic hypotension; PD=Parkinson disease.

Pharmacologic Treatment for Orthostatic Hypotension/ Neurogenic Orthostatic Hypotension
---------------------------------------------------------------------------------------

Pharmacologic treatment for OH/nOH is recommended in patients with PD whose symptoms are not relieved by non-pharmacologic approaches \[[@b26-ad-11-3-679]\]. Such treatment should be considered as an initial approach when patients have been experiencing syncope, presyncope, lightheadedness, or falls attributable to a drop in BP \[[@b26-ad-11-3-679]\].

A list of approved and off-label pharmacologic interventions for OH/nOH is provided in [Table 5](#T5-ad-11-3-679){ref-type="table"} \[[@b26-ad-11-3-679],[@b37-ad-11-3-679],[@b90-ad-11-3-679],[@b91-ad-11-3-679]\]. Several products (eg, fludrocortisone, indomethacin, pyridostigmine, and dihydroergotamine) are off-label options for the management of OH; however, some are supported only by limited clinical trial data that go back several decades \[[@b26-ad-11-3-679],[@b37-ad-11-3-679]\]. Drugs approved by the US Food and Drug Administration specifically for the treatment of symptomatic OH or nOH include the α~1~-adrenoreceptor prodrug midodrine indicated for OH \[[@b90-ad-11-3-679]\] and the norepinephrine prodrug droxidopa (L-*threo-*dihydroxyphenylserine) indicated for nOH \[[@b91-ad-11-3-679]\]. In Japan, droxidopa (originally known as L-DOPS) has been approved and used since 1989 for OH \[[@b92-ad-11-3-679]\]. In double-blind studies for patients with nOH, treatment with midodrine (10 or 20 mg, 1-3 times daily) resulted in significant improvements in standing systolic and diastolic BP and in symptoms of nOH such as lightheadedness \[[@b93-ad-11-3-679],[@b94-ad-11-3-679]\].

In an integrated analysis of randomized, placebo-controlled, double-blind clinical study data, patients with nOH (two-thirds of whom had an underlying diagnosis of PD) treated with droxidopa exhibited improvements in standing systolic BP compared with placebo. In addition, there was a reduction in symptoms of nOH (such as dizziness and lightheadedness) after 1 week of droxidopa treatment compared with placebo \[[@b95-ad-11-3-679]\]. In another 10-week, multicenter, randomized, double-blind study in 225 patients with PD and symptomatic nOH, droxidopa treatment was associated with fewer falls and fall-related injuries (eg, contusions, lacerations) compared with placebo. In the latter study, the beneficial effects of droxidopa on nOH may have contributed to the observed reduction in falls \[[@b96-ad-11-3-679]\]. Findings of patient experiences in a post hoc analysis of this study suggest that droxidopa also reduced fear of falling \[[@b97-ad-11-3-679]\].

A 6-month, non-interventional, prospective cohort study in 179 patients newly initiating droxidopa for the treatment of nOH (including 59 patients with PD and nOH) showed that significant improvements from baseline were achieved in nOH symptoms (*P*\<0.01), functionality (*P*\<0.01), and health-related QoL parameters (*P*≤0.002) during 1 month of droxidopa treatment \[[@b70-ad-11-3-679]\]. The improvements in nOH symptoms noted at 1 month persisted at 3 and 6 months during continued treatment \[[@b70-ad-11-3-679]\]. Dizziness/lightheadedness symptoms were improved at all assessments (1, 3, and 6 months; *P*\<0.01 for all). The proportion of patients reporting ≥1 fall in the previous month was also reduced from 51% at baseline to 40% at 6 months after starting droxidopa (11% reduction; *P*=0.03) \[[@b70-ad-11-3-679]\]. Other observations from this study at 6 months included significant improvements in fear of falling, functional impairment, depressive symptoms, and health-related QoL scores \[[@b70-ad-11-3-679]\]. However, because this study lacked a contemporaneous control group, the ability to establish causality is limited and additional studies comparing droxidopa with other treatment options in patients with similar comorbidities and disease severity are necessary \[[@b70-ad-11-3-679]\].

In PD patients receiving levodopa and, in some instances, a dopaminergic receptor agonist, the co-administration of droxidopa was associated with improvement in the part 2 ADL scores on the Unified Parkinson's Disease Rating Scale (UPDRS) in a randomized, placebo-controlled, double-blind study \[[@b98-ad-11-3-679]\]. However, because symptoms of nOH were not evaluated in the patients in this study, it is not possible to determine if the improved UPDRS part 2 scores were related to lessening symptoms of nOH.

###### 

Pharmacologic Treatments for nOH/OH.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication                                            Level of Evidence \[[@b99-ad-11-3-679]\]   Comments
  ----------------------------------------------------- ------------------------------------------ ----------------------------------------------------------------------------
  Droxidopa \[[@b26-ad-11-3-679],[@b91-ad-11-3-679]\]   A                                          •FDA approved for symptomatic nOH

  Midodrine \[[@b37-ad-11-3-679],[@b90-ad-11-3-679]\]   A                                          •FDA approved for symptomatic OH

  Fludrocortisone \[[@b37-ad-11-3-679]\]                C                                          •First-line monotherapy for OH\
                                                                                                   •Full benefit requires high dietary salt and adequate fluid intake

  Octreotide \[[@b37-ad-11-3-679]\]                     C                                          •May be used 30 minutes before a meal to reduce postprandial OH

  Pyridostigmine \[[@b26-ad-11-3-679]\]                 C                                          •For patients with less severe symptoms with residual sympathetic function

  Ephedrine \[[@b37-ad-11-3-679]\]                      N/A                                        •Considered GPP but no clear evidence for use in OH

  Yohimbine \[[@b37-ad-11-3-679]\]                      N/A                                        •Considered GPP but no clear evidence for use in OH\
                                                                                                   •Has been used in refractory OH

  Dihydroergotamine \[[@b37-ad-11-3-679]\]              N/A                                        •Considered GPP but no clear evidence for use in OH\
                                                                                                   •Has been used in severe OH

  Desmopressin \[[@b37-ad-11-3-679]\]                   N/A                                        •Considered GPP but no clear evidence for use in OH

  Erythropoietin \[[@b37-ad-11-3-679]\]                 N/A                                        •Considered GPP but no clear evidence for use in OH\
                                                                                                   •Recommended in anemic patients

  Indomethacin \[[@b37-ad-11-3-679]\]                   N/A                                        •Considered GPP but no clear evidence for use in OH\
                                                                                                   •Has been used in severe OH
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FDA=US Food and Drug Administration; GPP=good practice point; N/A=not applicable; nOH=neurogenic orthostatic hypotension; OH=orthostatic hypotension.

Conclusions
===========

The risk of falls and fall-related injuries is high among elderly patients with PD and is associated with a negative clinical impact, reduced QoL, and, consequently, an increased economic burden on healthcare. In patients with PD, OH and nOH are important risk factors for falls and further contribute to the burden of disease. Screening for OH/nOH and consideration of appropriate non-pharmacologic strategies and pharmacologic treatments (including lowering the doses of medications that may exacerbate symptoms) are important in the management of elderly patients with PD. The multifactorial risk profile for falls in patients with PD suggests that clinicians should consider a broad range of etiologies, including commonly used medications for lowering BP, when planning treatment management strategies.
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